What COVID-19 means for people with breast cancer
Dr Barbara Lipert, a research fellow at the University of Auckland, is investigating resistance to Kadcyla, a relatively new drug for advanced HER2+ breast cancer that has been recommended for funding by PHARMAC, but with a low priority ranking until further investigations are completed.
Dr Lipert plans to build on work at Auckland University that has already identified several genes that could be factors in resistance to Kadcyla. “We need to evaluate these findings in a multistage process now. This knowledge will help clinicians and patients make informed decisions in choosing the best treatment strategy, bringing us closer to making personalised medicine a reality in breast cancer treatment in New Zealand.”